If they have reached a dead end then they would have to tell us. Clearly that is material news if they have exhausted all partnership / buyout talks.
Silence=negotiations ongoing. IMHO
For the record I have been saying for awhile its a buyout. I will be just as happy with a good partnership. For those of you who have enjoyed a buyout, its clean sweet and profitable.
I also agree that PR is lacking but, ironically, the silence makes me believe they are digging in and finalizing a deal, in whatever form.
I agree with you. One of the best investing opportunities out there is when a good company gets punished by a market wide correction. The potential is still there just cheaper than it should be.
Good luck. I'm hoping for a great partnership announcement any day.
Take a look back at the April pre-ADCOM manipulation if you want to see what kind of Ba!!s is takes to play these stocks.
I held then. I am holding now. I've just a little more I am willing to put in at the right price.
Good luck to all longs.
Of course and I hope adn think they will. (I've actually been of the opinion for some time that Afrezza and GLP will be sold)
Its always best to try and consider the extremes in your investment thesis I think.
My point is that even in a worst case scenario MNKD is still a good investment.
Yes yes of course Derek my mistake. Watching tv n posting on phone. Thank you for correction but yes you get my point. Worst case isnt bad at all right?
Mnkd goes it alone. 25% stock dilution. New stock count 500million fully diluted. 250million in sales 18 price multiple = 9.00 a share. 1 billion in sales with 18 price multiple = 36.00 a share or a 300% gain.
If you don't believe 1billion in sales is not only attainable but likely on the low end if expectations sell now and go away.
I'm holding and adding on this round of manipulation.
I agree Kevin. The price drop yesterday prompted by a weak article is clearly manipulation. I added on the drop as IMHO the manipulation is a sign that the announcement is near.
I hope so mike! Today's performance was pathetic. 6% off the index. This silence is getting OLD and PLAYED out.
Make no mistake about it..... that was one of the most pathetic performances by this stock in some time. Biotech index up 4% and we are down 2% We have had bad days in the recent past driven by market biotech index moves but this was just pathetic today. 6% differential. People can say be patient until they are blue in the face but at some point its time for results!!?
We seem to be having some mild manipulation today. Not of the magnitude you are talking about but we have broken to the downside compared to the biotech indexes today.
I was giving two hypothetical extremes, simply indicating that either extreme is still potentially profitable.
If you can see into the future glue please let us know exactly whats going to happen?
They allowed them to include the graphs showing PK/PD profile that is clear as day to any scientist or physician. One of the post marketing studies, when completed will allow them to make this claim in the label. Regarding hypoglycemia there is nothing to prevent reps from directing docs to reference published studies showing hypoglycemia benefit.
I'm ready for news last week believe me! I have to believe the silence is a good thing.
I too am impatient at this point keven.
As I see it we have two extremes. One one extreme we have immediate gratification: buyout 27.50 a share.
On the other extreme we have go it alone mnkd rough times in the near term but possibly 100.00 a share if launch is completed on a go it alone basis. I calculate approx 25% dilution to go it alone. Long term anything north of 12.50 a share is profitable.
For the record I prefer scenario one and immediate gratification. It is my hope that it is scenario one combined with splitting off technosphere into a stand alone company that is dragging the process out.
Good luck to all longs.
Though I regularly discount Novo and LLY as partners due to the fact that they would first have to erode their own products to make Afrezza successful, it is important to note that insulin IS the raw material for Afrezza.
If they aggressively marketed Afrezza for type II and not type I maybe they could make it work. Couple this with the fact that they would recover some lost revenue by providing the insulin?? INHO NOVO has the more aggressive and forward thinking CEO.
However LLY is the pioneer historically in the insulin market. Just speculation but what else do we have at this point?